Seven Eight Capital, LP Catalent, Inc. Transaction History

Seven Eight Capital, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$72.36 - $113.1 $492,843 - $770,324	6,811 New	6,811 $493,000
Q4 2021 Feb 14, 2022	SELL	$119.57 - $139.07 $729,018 - $847,909	-6,097 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$109.17 - $142.35 $403,929 - $526,695	3,700 Added 154.36%	6,097 $811,000
Q2 2021 Aug 13, 2021	SELL	$100.34 - $115.69 $301 - $347	-3 Reduced 0.13%	2,397 $259,000
Q4 2020 Feb 09, 2021	SELL	$85.88 - $105.36 $626,924 - $769,128	-7,300 Reduced 75.26%	2,400 $250,000
Q3 2020 Nov 16, 2020	BUY	$72.74 - $92.5 $705,578 - $897,250	9,700 New	9,700 $831,000
Q1 2019 May 15, 2019	SELL	$29.84 - $43.92 $423,728 - $623,664	-14,200 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$29.95 - $46.34 $92,845 - $143,654	3,100 Added 27.93%	14,200 $443,000
Q3 2018 Oct 18, 2018	BUY	$40.12 - $45.55 $445,332 - $505,604	11,100 New	11,100 $506,000
Q4 2017 Feb 12, 2018	SELL	$37.27 - $43.02 $1.32 Million - $1.53 Million	-35,500 Closed	0 $0
Q3 2017 Oct 16, 2017	SELL	$33.75 - $41.67 $1.38 Million - $1.71 Million	-41,000 Reduced 53.59%	35,500 $1.42 Million
Q2 2017 Aug 10, 2017	BUY	N/A	76,500	76,500 $2.69 Million

514

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.